Organization Profile

You just read:

Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with Capecitabine and/or Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

News provided by

Oncothyreon Inc.

Feb 03, 2014, 08:00 ET